Synthesis of 11C Labeled Lansoprazole: A Novel Radiopharmaceutical for the Diagnosis of Alzheimer’s Disease

Garrett Michael Carpenter


Alzheimer’s disease is a serious and common form of dementia, affecting nearly half of the population over 85 years of age (Source: Mayo Clinic). As of now, this disease has no cure and can only be definitively diagnosed by risky diagnostic procedures such as brain biopsy or upon post-mortem examination of the brain. The cause of Alzheimer’s disease is not completely understood and is often contributed to several compounding factors know as a neurodegenerative cascade. One theory is that abnormal aggregates of tau protein, called neurofibrillary tangles (NFT’s), build up in the brain, causing a disruption in neuronal functioning which leads to cognitive decline. The focus of this research is to develop a chemical radiolabeling technique to label lansoprazole, a drug that has shown a high affinity for tau tangles, with carbon-11. The resulting drug will be used to image tau tangles using positron emission tomography (PET). The products of the reactions are characterized with various methods including HPLC, TLC, and NMR. Future imaging studies with rodents will be used to determine if the biomarker developed is a realistic radioligand for PET imaging of tau. It is anticipated that these drugs will provide information about the density and mass of tau tangles that could one day be used to diagnose various tauopathies, select appropriate patients for the development of tau-based therapeutics, and monitor patient response to therapy. The results of radiopharmaceutical synthesis will be reported.


PET, Alzheimer’s disease, Radiochemistry

Full Text:  Subscribers Only


  • There are currently no refbacks.

The Proceedings is produced as a service of UNC Asheville.